Related Experiment Videos
Optimal utilization of thrombolytic therapy for acute myocardial infarction: concepts and controversies
1Department of Medicine, University of Kentucky Medical Center, Lexington 40536-0084.
Insights
Thrombolytic therapy significantly reduces mortality and improves outcomes for myocardial infarction patients, even in specific controversial groups like the elderly or those presenting later. Early treatment is key for better survival rates.
Area of Science:
- Cardiology
- Emergency Medicine
- Pharmacology
Background:
- Thrombolytic therapy is crucial for reducing myocardial infarct size, congestive heart failure, and improving survival.
- Current utilization of thrombolytic drugs in the US is low (around 10%) due to perceived risks.
- Risk-benefit ratio remains controversial in specific patient subgroups, including those with inferior infarction, delayed presentation, elderly patients, and those with hypertension.
Purpose of the Study:
- To evaluate the efficacy and safety of thrombolytic therapy across diverse patient populations with acute myocardial infarction.
- To clarify the benefits of thrombolytic therapy in patient groups where its use is debated.
Main Methods:
- Analysis of pooled data from multiple thrombolytic trials.
- Inclusion of data from approximately 12,000 patients with inferior infarction.
- Examination of outcomes based on infarct location, time from symptom onset, electrocardiogram findings, age, and hemodynamic status.
Main Results:
- Mortality reduction was observed independently of infarct location.
- Significant mortality reduction (6.8% vs. 8.7%) and improved left ventricular function in inferior infarction patients.
- Lower mortality in patients treated 6-24 hours after symptom onset (11.1% vs. 13.1%) and in those with ST elevation or left bundle branch block.
- Elderly patients may have a two to three times greater lifesaving potential from thrombolytic therapy.
- Patients with hypotension, hypertension, or who underwent cardiopulmonary resuscitation may also benefit.
Conclusions:
- Thrombolytic therapy offers significant survival benefits across a broader range of myocardial infarction patients than previously assumed.
- Age and presentation time (up to 24 hours) should not be absolute contraindications.
- Further research and guideline updates are warranted to optimize thrombolytic therapy use in all eligible patients.
Abstract:
Timely administration of thrombolytic therapy decreases myocardial infarct size, lessens the incidence of congestive heart failure and improves survival. However, available data suggest that only 10% of patients with acute infarction in the United States receive thrombolytic drugs. Given the benefits of thrombolytic therapy, all patients with myocardial infarction would likely be treated were it not for associated risks. Several groups exist in which the risk/benefit ratio of thrombolytic therapy continues to be controversial, including those with inferior infarction, absence of ST segment elevation or presentation greater than 6 h from symptom onset, elderly patients and those with hypertension. Three recent thrombolytic trials reported a reduction in mortality that was entirely independent of infarct location. Pooled data from trials involving 12,000 patients with inferior infarction have demonstrated a reduction in mortality rate (6.8% versus 8.7%, p less than 0.0001). Furthermore, improvement in regional and global left ventricular function occurred after reperfusion therapy of inferior infarction. Pooled data indicate that patients treated between 6 and 24 h after symptom onset have a lower mortality rate than do those who receive placebo (11.1% versus 13.1%, p less than 0.001). Improved survival occurs after thrombolytic therapy in patients with ST segment elevation or left bundle branch block, but not in those with isolated ST depression or a normal electrocardiogram. Age should not be considered an absolute contraindication because the lifesaving potential of thrombolytic therapy in the elderly may be two to three times that of the overall group of patients with myocardial infarction. Finally, recent studies demonstrated that patients who present with hypotension or hypertension or who have undergone cardiopulmonary resuscitation may also benefit.(ABSTRACT TRUNCATED AT 250 WORDS)